Kailera Therapeutics, a biotechnology company focused on obesity treatments, filed for an initial public offering on March 27. The filing comes after a slow year for IPOs in 2025, when only eight companies went public—the lowest number since the pandemic era.
Industry observers say that the market is becoming more selective, favoring drug developers with proven assets in later stages of development. “We are likely in/entering a more discerning IPO marketplace where drug innovators with proven, later-stage assets/programs will have the necessary support to go public,” Michael Rachlin, senior managing director at FTI Consulting’s Corporate Finance & Restructuring unit, told BioSpace in January.
Despite last year's slowdown, Rachlin said he remains optimistic about biopharma IPO prospects in 2026. “The development and commercialization of novel and innovative drugs will continue to be a cornerstone of health and wellness, and a robust IPO market will continue to be an important factor for drug innovators to access capital and liquidity,” Rachlin said.
Kailera's lead therapy is ribupatide, a once-weekly injectable GLP-1/GIP receptor agonist developed from assets acquired from China’s Hengrui. In Phase 2 testing involving people with obesity in China, ribupatide showed an average weight loss of 12% after 26 weeks without plateauing. The therapy is now being tested globally in Phase 3 trials under the KaiNETIC program. Proceeds from Kailera's planned IPO will fund further development of both injectable and oral versions of ribupatide as well as other pipeline candidates such as KAI-7535 and KAI-4729.
Other companies also recently entered or plan to enter the public markets. Generate:Biomedicines raised $400 million through its February debut on Nasdaq; Eikon Therapeutics secured $381 million; AgomAb Therapeutics aims for $212.5 million; SpyGlass Pharma targeted $150 million; Veradermics sought $256.3 million; and Aktis Oncology opened the year with a $318 million raise.
Looking ahead, industry analysts expect that successful late-stage clinical results could drive renewed investor interest throughout this year.
